Maiden Cove Capital LLC Has $1.11 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Maiden Cove Capital LLC cut its stake in shares of Eli Lilly and Company (NYSE:LLY) by 1.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,439 shares of the company’s stock after selling 24 shares during the period. Eli Lilly and Company comprises approximately 1.7% of Maiden Cove Capital LLC’s investment portfolio, making the stock its 13th largest holding. Maiden Cove Capital LLC’s holdings in Eli Lilly and Company were worth $1,111,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Montis Financial LLC boosted its stake in Eli Lilly and Company by 46.4% in the fourth quarter. Montis Financial LLC now owns 751 shares of the company’s stock valued at $580,000 after acquiring an additional 238 shares during the last quarter. Buckley Wealth Management LLC boosted its holdings in shares of Eli Lilly and Company by 3.6% in the fourth quarter. Buckley Wealth Management LLC now owns 546 shares of the company’s stock worth $422,000 after acquiring an additional 19 shares during the period. United Capital Management of KS Inc. raised its stake in shares of Eli Lilly and Company by 0.7% during the 4th quarter. United Capital Management of KS Inc. now owns 12,317 shares of the company’s stock valued at $9,509,000 after purchasing an additional 84 shares during the period. Associated Banc Corp lifted its holdings in Eli Lilly and Company by 95.5% during the 4th quarter. Associated Banc Corp now owns 51,403 shares of the company’s stock worth $39,683,000 after purchasing an additional 25,104 shares in the last quarter. Finally, HMV Wealth Advisors LLC purchased a new stake in Eli Lilly and Company during the 4th quarter worth about $1,238,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Trading Up 1.5 %

LLY stock opened at $813.55 on Friday. The company has a market capitalization of $771.38 billion, a PE ratio of 69.47, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a one year low of $711.40 and a one year high of $972.53. The company’s 50 day moving average price is $830.81 and its two-hundred day moving average price is $844.01.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company declared that its Board of Directors has approved a stock repurchase program on Monday, December 9th that permits the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization permits the company to repurchase up to 2% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s leadership believes its shares are undervalued.

Insider Activity

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares of the company’s stock, valued at $4,778,521.60. The trade was a 14.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.13% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

LLY has been the topic of several analyst reports. Citigroup decreased their price target on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. Morgan Stanley set a $1,146.00 price target on shares of Eli Lilly and Company in a report on Thursday, March 6th. Leerink Partners set a $950.00 price target on shares of Eli Lilly and Company in a report on Friday, January 17th. Berenberg Bank set a $970.00 price objective on Eli Lilly and Company in a research note on Thursday, January 16th. Finally, StockNews.com upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Three investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,009.72.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.